Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCA | P06881 | 2/20 | 0.71 |
| ▸ | NPY1R | P25929 | 1/20 | 0.66 |
| ▸ | NPY2R | P49146 | 1/20 | 0.66 |
| ▸ | NPY4R | P50391 | 1/20 | 0.66 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.66 |
| ▸ | GNRHR | P30968 | 1/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.62 |
| ▸ | GLP1R | P43220 | 10/20 | 0.62 |
| ▸ | NMBR | P28336 | 1/20 | 0.61 |
| ▸ | GRPR | P30550 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060386 | 0.90 | CALCA (0.75) | CALCANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30429251 | 0.89 | CALCA (0.62) | CALCANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30523133 | 0.87 | GLP1R (0.71) | CALCANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30932197 | 0.87 | GLP1R (0.71) | CALCANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL31251982 | 0.86 | CALCA (0.90) | CALCANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29992945 | 0.86 | CALCA (0.59) | CALCANPY1RNPY2RNPY4RNPY5R | |
| Exenatide SCHEMBL30947451 | 0.84 | GLP1R (0.79) | GLP1R | |
| SCHEMBL29358003 | 0.84 | NR3C1 (0.66) | GLP1R | |
| SCHEMBL29351953 | 0.84 | NPY2R (0.74) | CALCANPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29983249 | 0.84 | NR3C1 (0.69) | GLP1RGRPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260140121-A1 | METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINS | LARIMAR THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260110698-A1 | METHODS FOR QUANTIFYING FRATAXIN ACTIVITY | LARIMAR THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-12577602-B2 | Compositions and methods for peptide production | BIOCATALYST LLC (US) | 2026-03-17 | — | — | US | disclosed |
| US-12566178-B2 | Methods of quantifying frataxin and frataxin fusion proteins | LARIMAR THERAPEUTICS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| WO-2025261963-A1 | THERAPEUTIC DELIVERY COMPOSITIONS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4638483-A1 | GALANIN-2 RECEPTOR AGONISTS | LifeArc (GB) | 2025-10-29 | — | — | EP | disclosed |
| US-12411145-B2 | Methods for quantifying frataxin activity | LARIMAR THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12351611-B2 | Molecules for organelle-specific protein delivery | LARIMAR THERAPEUTICS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| CN-120154732-A | Combination comprising a galanin receptor GAL2R agonist for the treatment of multiple sclerosis | 深圳先进技术研究院 | 2025-06-17 | — | — | CN | disclosed |
| US-20250085297-A1 | METHODS FOR QUANTIFYING FRATAXIN ACTIVITY | LARIMAR THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| US-20240026414-A1 | Compositions and Methods for Peptide Production | BIOCATALYST LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11802301-B2 | Compositions and methods for peptide production | BIOCATALYST LLC (US) | 2023-10-31 | — | — | US | disclosed |
| US-20230193342-A1 | Compositions and Methods for Peptide Production | BIOCATALYST LLC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | APELLIS PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
| CN-115725000-A | Double-label recombinant protein for expressing and purifying small peptide and preparation method and application thereof | 中国科学技术大学 | 2023-03-03 | — | — | CN | disclosed |
| US-20220378869-A1 | USE OF FRATAXIN FOR TREATING LEIGH SYNDROME, FRENCH CANADIAN TYPE | LARIMAR THERAPEUTICS, INC. | 2022-12-01 | — | — | US | disclosed |
| US-20220287968-A1 | LIPID VESICLE-MEDIATED DELIVERY TO CELLS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-09-15 | — | — | US | disclosed |
| US-20220265843-A1 | EXTRACELLULAR VESICLE-MEDIATED DELIVERY TO CELLS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2022-08-25 | — | — | US | disclosed |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | APELLIS PHARMACEUTICALS, INC. (US) | 2022-08-09 | — | — | US | disclosed |
| US-20220088131-A1 | COMPOSITIONS AND METHODS RELATING TO C5L2 | KING'S COLLEGE LONDON (GB) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577602-B2 | Compositions and methods for peptide production | LNPEP, CPN1, PRCP | CALCA 52/4885NPY1R 509/4885NPY2R 824/4885 |
| US-12566178-B2 | Methods of quantifying frataxin and frataxin fusion proteins | FGB, GZMB, TAF15 | CALCA 575/4885NPY1R 385/4885NPY2R 677/4885 |
| US-20230075121-A1 | CELL-PENETRATING COMPSTATIN ANALOGS AND USES THEREOF | C9, C3AR1, SERPINC1 | CALCA 176/4885NPY1R 3275/4885NPY2R 3717/4885 |
| US-20260110698-A1 | METHODS FOR QUANTIFYING FRATAXIN ACTIVITY | ATXN2L, XDH, CYFIP1 | CALCA 1825/4885NPY1R 482/4885NPY2R 997/4885 |
| US-20260140121-A1 | METHODS OF QUANTIFYING FRATAXIN AND FRATAXIN FUSION PROTEINS | TFAM, TIMM10, AFG3L2 | CALCA 671/4885NPY1R 436/4885NPY2R 446/4885 |
| US-11407789-B2 | Cell-penetrating compstatin analogs and uses thereof | C9, C3AR1, SERPINC1 | CALCA 172/4885NPY1R 3248/4885NPY2R 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.